retatrutide clinical trial thailand patientsafety #publichealth #healthcareleadership #medicalethics #drugsafety #unapproveddrugs #clinicaltrials #npra #fda #weightlossdrugs #healthawareness ESC 2024: Retatrutide improves lipid

Clinical trial data from the SURMOUNT and SURPASS programs did not show dramatic differences in efficacy between abdominal, thigh, and upper arm injections for the majority of participants

Limit processed foods, sugary drinks, and excessive simple carbohydrates

2024]Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

But the trajectory is clear: we are entering a new era where the boundaries between metabolic medicine and addiction treatment are blurring and thats a good thing

Most patients describe the sensation as a brief pinch

But the differences between them particularly the addition of glucagon receptor (GCGR) agonism in retatrutide produce meaningfully distinct experimental profiles that influence which compound belongs in a given study design